A role for IgG immune complexes during infection with the intracellular pathogen Leishmania

Journal of Experimental Medicine

Volumn 201, Issue 5, 2005, Pages 747-754

  Miles, Suzanne A ^a   Conrad, Sean M ^a   Alves, Renata G ^b   Jeronimo, Selma M B ^b   Mosser, David M ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE EXACERBATION; HUMAN; LEISHMANIA; MACROPHAGE; MOUSE; NONHUMAN; PARASITE; PATHOGENESIS; PRIORITY JOURNAL; PROTOZOAL INFECTION; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; CELLS, CULTURED; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; INTERLEUKIN-10; LEISHMANIA MAJOR; LEISHMANIASIS; MICE; MICE, INBRED BALB C; MONOCYTES;

EID: 15444364277     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20041470     Document Type: Article

References (39)

1. Berman, J. 2003. Current treatment approaches to leishmaniasis. Curr. Opin. Infect. Dis. 16:397-401.
2. Melby, P.C. 2002. Recent developments in leishmaniasis. Curr. Opin. Infect. Dis. 15:485-490.
3. Kane, M.M., and D.M. Mosser. 2001. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166:1141-1147.
4. Noben-Trauth, N., R. Lira, H. Nagase, W.E. Paul, and D.L. Sacks. 2003. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 170:5152-5158.
5. Murray, H.W., C.M. Lu, S. Mauze, S. Freeman, A.L. Moreira, G. Kaplan, and R.L. Coffman. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70:6284-6293.
6. Karp, C.L., S.H. el Safi, T.A. Wynn, M.M. Satti, A.M. Kordofani, F.A. Hashim, M. Hag-Ali, F.A. Neva, T.B. Nutman, and D.L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest. 91:1644-1648.
7. Lang, R., R.L. Rutschman, D.R. Greaves, and P.J. Murray. 2002. Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. J. Immunol. 168:3402-3411.
8. Mosser, D.M. 2003. The many faces of macrophage activation. J. Leukoc. Biol. 73:209-212.
9. Sutterwala, F.S., G.J. Noel, R. Clynes, and D.M. Mosser. 1997. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J. Exp. Med. 185:1977-1985.
10. Sutterwala, F.S., G.J. Noel, P. Salgame, and D.M. Mosser. 1998. Reversal of proinflammatory responses by ligating the macrophage Fcγ receptor type I. J. Exp. Med. 188:217-222.
11. Anderson, C.F., and D.M. Mosser. 2002. Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J. Immunol. 168:3697-3701.
12. Locksley, R.M., and P. Scott. 1991. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Immunol. Today. 12:A58-A61.
13. Liu, Y., M.R. de Waal, F. Briere, C. Parham, J.M. Bridon, J. Banchereau, K.W. Moore, and J. Xu. 1997. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J. Immunol. 158:604-613.
14. Hsieh, C.S., S.E. Macatonia, C.S. Tripp, S.F. Wolf, A. O'Garra, and K.M. Murphy. 1993. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 260:547-549.
15. Junqueira, P.M., M. Orsini, M. Castro, V.M. Passos, and A. Rabello. 2003. Antibody subclass profile against Leishmania braziliensis and Leishmania amazonensis in the diagnosis and follow-up of mucosal leishmaniasis. Diagn. Microbiol. Infect. Dis. 47:477-485.
16. Kima, P.E., S.L. Constant, L. Hannum, M. Colmenares, K.S. Lee, A.M. Haberman, M.J. Shlomchik, and D. McMahon-Pratt. 2000. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J. Exp. Med. 191:1063-1068.
17. Belkaid, Y., C.A. Piccirillo, S. Mendez, E.M. Shevach, and D.L. Sacks. 2002. CD4+ CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 420:502-507.
18. Stenger, S., N. Donhauser, H. Thuring, M. Rollinghoff, and C. Bogdan. 1996. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183:1501-1514.
19. von Stebut, E., Y. Belkaid, T. Jakob, D.L. Sacks, and M.C. Udey. 1998. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J. Exp. Med. 188:1547-1552.
20. Anderson, C.F., M. Lucas, L. Gutierrez-Kobeh, A.E. Field, and D.M. Mosser. 2004. T cell biasing by activated dendritic cells. J. Immunol. 173:955-961.
21. Pearson, R.D., T.G. Naidu, A.C. Young, J.E. de Alencar, R. Romito, and J.S. Davis. 1983. Circulating immune complexes and rheumatoid factors in visceral leishmaniasis. J. Infect. Dis. 147:1102.
22. Carvalho, E.M., B.S. Andrews, R. Martinelli, M. Dutra, and H. Rocha. 1983. Circulating immune complexes and rheumatoid factor in schistosomiasis and visceral leishmaniasis. Am. J. Trop. Med. Hyg. 32:61-68.
23. Galvao-Castro, B., J.A. Sa Ferreira, K.F. Marzochi, M.C. Marzochi, S.G. Coutinho, and P.H. Lambert. 1984. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis. Clin. Exp. Immunol. 56:58-66.
24. Quinnell, R.J., O. Courtenay, L.M. Garcez, P.M. Kaye, M.A. Shaw, C. Dye, and M.J. Day. 2003. IgG subclass responses in a longitudinal study of canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 91:161-168.
25. Hailu, A., J.N. Menon, N. Berhe, L. Gedamu, T.H. Hassard, P.A. Kager, J. Olobo, and P.A. Bretscher. 2001. Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. J. Infect. Dis. 184:112-115.
26. Howard, J.G., C. Hale, and W.L. Chan-Liew. 1980. Immunological regulation of experimental cutaneous leishmaniasis. I. Immunogenetic aspects of susceptibility to Leishmania tropica in mice. Parasite Immunol. 2:303-314.
27. Andrade, Z.A., S.G. Reed, S.B. Roters, and M. Sadigursky. 1984. Immunopathology of experimental cutaneous leishmaniasis. Am. J. Pathol. 114:137-148.
28. Sacks, D.L., P.A. Scott, R. Asofsky, and F.A. Sher. 1984. Cutaneous leishmaniasis in anti-IgM-treated mice: enhanced resistance due to functional depletion of a B cell-dependent T cell involved in the suppressor pathway. J. Immunol. 132:2072-2077.
29. Halstead, S.B., and E.J. O'Rourke. 1977. Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 265:739-741.
30. Bleharski, J.R., H. Li, C. Meinken, T.G. Graeber, M.T. Ochoa, M. Yamamura, A. Burdick, E.N. Sarno, M. Wagner, M. Rollinghoff, et al. 2003. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science. 301:1527-1530.
31. Rivera, J., J. Mukherjee, L.M. Weiss, and A. Casadevall. 2002. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J. Immunol. 168:3419-3427.
32. Teitelbaum, R., A. Glatman-Freedman, B. Chen, J.B. Robbins, E. Unanue, A. Casadevall, and B.R. Bloom. 1998. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc. Natl. Acad. Sci. USA. 95:15688-15693.
33. Evans, T.G., M.J. Teixeira, I.T. McAuliffe, I. Vasconcelos, A.W. Vasconcelos, A.A. Sousa, J.W. Lima, and R.D. Pearson. 1992. Epidemiology of visceral leishmaniasis in northeast Brazil. J. Infect. Dis. 166:1124-1132.
34. Braz, R.F., E.T. Nascimento, D.R. Martins, M.E. Wilson, R.D. Pearson, S.G. Reed, and S.M. Jeronimo. 2002. The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am. J. Trop. Med. Hyg. 67:344-348.
35. Reed, S.G., W.G. Shreffler, J.M. Burns Jr., J.M. Scott, M.G. Orge, H.W. Ghalib, M. Siddig, and R. Badaro. 1990. An improved serodiagnostic procedure for visceral leishmaniasis. Am. J. Trop. Med. Hyg. 43:632-639.
36. O'Farrell, A.M., Y. Liu, K.W. Moore, and A.L. Mui. 1998. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J. 17:1006-1018.
37. Love, D.C., J.D. Esko, and D.M. Mosser. 1993. A heparin-binding activity on Leishmania amastigotes which mediates adhesion to cellular proteoglycans. J. Cell Biol. 123:759-766.
38. Teixeira, M.C., S.R. de Jesus, R.B. Sampaio, L. Pontes-de-Carvalho, and W.L. dos-Santos. 2002. A simple and reproducible method to obtain large numbers of axenic amastigotes of different Leishmania species. Parasitol. Res. 88:963-968.
39. Ji, J., J. Sun, and L. Soong. 2003. Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis. Infect. Immun. 71:4278-4288.